Stay at the forefront of interventions for valvular heart disease, coronary, and structural interventions with expert insights and perspectives. These interviews explore the techniques, tools, and key topics shaping the ever-evolving field of interventional cardiology
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Fabien Praz and Neil Fam talk about the management of patients with combined mitral and tricuspid regurgitation, who are often elderly with heart failure and multiple comorbidities. Careful assessment—including echocardiography, hemodynamics, and sometimes CT—is crucial to identify the dominant lesion. Surgery is preferred if feasible, but for high-risk patients, transcatheter repair or replacement is considered. Hosted on Acast. See acast.com/privacy for more information....
Bernard Prendergast and Fabien Praz discuss updates from the new ESC/EACTS guidelines on aortic stenosis. Key changes include expanding TAVI to patients aged 70 and older, supporting early intervention in asymptomatic patients, and providing guidance for bicuspid aortic valves. These updates emphasise shared decision-making, careful patient selection, and lifetime management strategies. Hosted on Acast. See acast.com/privacy for more information.
Lukas Stolz and Rebecca Hahn discuss advances in transcatheter tricuspid valve intervention, emphasising that reducing tricuspid regurgitation (TR) to mild levels is key for improving patient outcomes, including mortality and heart failure hospitalisations. Decision-making between transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) depends on anatomy, imaging, and patient factors like pacemakers or bleeding risk. Hosted on Acast. See acast.com/privacy ...
Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects causing significant shunting need closure to prevent right heart overload. Some moderate defects may be beneficial by decompressing the left atrium, so closure isn’t always needed. With the increasing amount of procedures, understanding the hemodynamics is also key to safe management. Hosted on Acast. See acast.com/privacy for more informati...
Tiffany Patterson and Davide Capodanno address the increasingly common scenario of managing coronary artery disease (CAD) in patients undergoing TAVI. With up to half of TAVI candidates presenting with CAD, they highlight new evidence from NOTION-3 showing that revascularization reduces major adverse cardiac events. The takeaway: CAD in TAVI patients matters, should be assessed thoughtfully, and evidence is evolving to guide both lesion selection and timing. Hosted on Acast. See acast.com/privac...
Francesco Maisano interviews Michael Borger, co-chair of the 2025 ESC/EACS valvular heart disease guidelines, on their practical impact. The updated guidelines emphasize earlier intervention in primary mitral regurgitation, especially for asymptomatic patients with risk factors, while surgery remains preferred for low-risk patients. Michael Borger stresses the importance of a multidisciplinary team approach, high-volume centres for complex cases, and timely, evidence-based interventions to impro...
Lorenz Räber and Kasper Korsholm highlight why pre-procedural imaging—particularly cardiac CT—has become essential for successful left atrial appendage occlusion (LAAO). They explain that the LAA is highly variable between patients, making detailed planning crucial for safety, device selection, and optimal procedural results. Hosted on Acast. See acast.com/privacy for more information.
Michael Joner and Francesco Saia discuss the newly developed D-PACE Score, a tool designed to predict delayed AV block occurring more than 24 hours after TAVI—an unmet clinical need given that current risk models focus mainly on early events. The next steps aim to refine the algorithm and integrate it into standardized pathways for conduction-disturbance management after TAVI. Hosted on Acast. See acast.com/privacy for more information....
In this #pcrlv2025 conversation, Ellen Ross and Marta Sitges discuss the recent initiative from Global Heart Hub, a patient association: an in-depth look at the situation of women living with heart valve disease, the gaps identified, and the call to action that followed. They reflect on what these specific needs are, why they’re often overlooked, and how clinicians can adapt their approach to offer more meaningful support to women throughout their journey. Hit play to hear their perspectives and...
Listen to this PCR London Valves 2025 interview with Philippe Généreux and Philippe Pibarot, who explore the 7-year results of PARTNER 3 in low-risk patients. They walk through the main findings of this TAVR versus SAVR comparison in symptomatic severe aortic stenosis (AS). At 7 years, the primary endpoint — the composite of mortality, stroke and rehospitalisation — shows similar rates between both strategies. The conversation then turns to valve durability and whether the early promises of TAVR...
While the PCR London Valves 2025 Course is underway, Francesco Maisano and Fabien Praz discuss how the latest ESC/EACTS valvular guidelines affect clinical practice. What’s changing in surgery? How do repair and replacement strategies differ under the new recommendations, and what’s the impact on transcatheter interventions? Discover key insights from this exclusive interview: watch the whole exchange now! Hosted on Acast. See acast.com/privacy for more information....
What makes TAVI in bicuspid aortic valve disease so challenging—and how can those challenges be overcome? In this #europcr 2025 expert discussion, Chiara De Biase, Kentaro Hayashida, and Didier Tchetche share practical insights on navigating anatomical variability, refining patient selection, and optimising valve sizing. They also address the critical role of calcification and how it can influence procedural outcomes. Whether you're performing TAVI in complex cases or building your expertise, th...
Jens Flensted Lassen and Giuseppe Di Gioia discuss the essentials of the provisional strategy for non-left main true bifurcation lesions, highlighting its stepwise, adaptable nature from a single stent to a potential two-stent technique. They delve into critical aspects like proximal optimization (POT), side branch protection, and the extensive role of imaging for guidance and complication identification. The conversation also introduces the innovative use of drug-coated balloons as a means to further limit metal deployment within the bifurcation segment, providing practical tips for this versatile approach.
Howard Herrmann and Raj Makkar discuss valve under-expansion in the ACURATE neo2 from the IDE trial sub-study. Fluoroscopy showed about 22 % of valves were under-expanded, often linked to heavy calcium buildup. These valves had worse outcomes, including higher rates of death and stroke. What’s behind this issue, and how can it be prevented? Listen to their #europcr 2025 discussion to learn more! Hosted on Acast. See acast.com/privacy for more information....
Robert Byrne and Bruno Scheller discuss drug-coated balloon (DCB) angioplasty at #europcr 2025. Nearly 20 years after its introduction, where does DCB angioplasty stand today? When and how should it be used in daily practice? Discover what defines adequate lesion preparation for a DCB strategy in de novo disease, the role of intravascular imaging in deciding when to use DCB, and best practices for managing dissections. Plus, get insights on upcoming data and the future of drug-coated balloon ang...
In this #europcr 2025 interview, Tanja Rudolph, Dan Blackman, and Radoslaw Parma explore the crucial aspects of repeat transcatheter valve replacement. They dive into the risks of coronary obstruction, the importance of preserving coronary access, and strategies to optimise hemodynamics despite higher residual gradients. The discussion also covers how the index TAVR device impacts outcomes and why CT screening is essential in planning. Tune in to get a clear picture of the current evidence and w...
Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux reveal the hottest emerging TAVI indications for 2025 in this #europcr 2025 discussion. They review key trials on asymptomatic severe aortic stenosis—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—which show early TAVI or surgery reduces hospitalisations for heart failure and suggests lower mortality and stroke compared to clinical surveillance. The discussion then moves to symptomatic moderate aortic stenosis, highlighting the recent TAVR ...
When should TAVI be performed—and how should coronary disease be managed in these patients? Liesbeth Rosseel, Davide Capodanno, and Michael Joner explore two key questions shaping the future of TAVI. They highlight findings from the EARLY-TAVI trial, which shows that early intervention in asymptomatic patients with severe aortic stenosis significantly reduces rehospitalisation. Then, they turn to the NOTION-3 trial, comparing PCI vs medical therapy for CAD prior to TAVI—revealing a benefit in re...
Simon Redwood interviews John Forrest, principal investigator of the Evolut Low Risk Bicuspid Study, during #europcr 2025. As TAVR moves into younger patients—many with bicuspid valves—questions remain about how well the procedure performs in this anatomy, which was excluded from earlier trials. In this exchange, they review the study design, patient selection, and main outcomes, and compare results with the original Evolut Low Risk study. The performance of the Evolut platform in bicuspid valve...
In this #europcr 2025 interview, Davide Capodanno and Woong Chol Kang explore the latest insights from the 4D-ACS trial and what it could mean for antithrombotic therapy in patients with acute coronary syndrome. They discuss who was included in the trial and walk through the two de-escalation strategies that were tested: reducing the number of the drugs, from dual antiplatelet therapy to single antiplatelet therapy, and lowering the prasugrel dose from 10 mg to 5 mg. Finally, they highlight the ...
What’s the best approach for STEMI patients with multivessel disease? Angela Mcinerney, Natalia Pinilla, and Matthias Götberg share their perspectives on how practice has evolved, with a focus on the COMPLETE trial and its intracoronary imaging substudy. They discuss what imaging reveals about non-culprit lesions, how it may influence treatment, and how these insights are applied in daily cathlab workflows. The conversation also touches on expectations from the upcoming COMPLETE-2 trial. Listen ...
In this #europcr 2025 video, Nicola Ryan speaks with Dejan Milasinovic about when and how to adopt an upfront two-stent strategy in bifurcation PCI. The key is assessing the side branch: if stenosis is high-grade and disease is extensive, treatment may be needed from the start—using POBA, a DCB, or a second stent. Anatomy should guide the choice between a provisional or two-stent approach. Intracoronary imaging is essential to detect issues like abluminal rewiring and stent distortion, especiall...
In this #europcr 2025 discussion, Mayra Guerrero, Thomas Modine, and Philipp Lurz share their views on the evolving landscape of mitral valve treatment. While transcatheter edge-to-edge repair (TEER) remains a safe and effective approach, it doesn’t work for every patient. That’s why alternatives like TMVR, annuloplasty, or NeoChords—all currently under investigation—are generating attention. The field is moving toward transseptal, transcatheter options that may deliver better reduction of mitra...
Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario. In this #europcr 2025 interview, Dejan Milasinovic, Miroslaw Ferenc, and Mohamed Abdel Wahab explore why this topic deserves special attention. They break down how intra-coronary imaging can guide the approach, help tailor strategy, and ultimately improve outcomes. Discover how to move beyond anatomy alone - by factoring in the patient’s cl...
How effective is cerebral protection during TAVI? Bernard Prendergast and Rajesh Kharbanda take a deep dive into this key procedural question, reviewing the latest evidence from two major randomised trials—PROTECTED TAVR and BHF PROTECT-TAVI. Although both studies individually failed to demonstrate a clinical benefit for cerebral protection devices, a new patient-level meta-analysis presented at #EuroPCR2025 offers fresh insights. Listen to this episode now to understand how aligning endpoints a...
In this exchange, Vijay Kunadian and Javier Escaned explore the real-world implementation of INOCA (Ischemia with Non-Obstructive Coronary Arteries) and ANOCA (Angina with Non-Obstructive Coronary Arteries) diagnostic pathways. Drawing on the 2024 CCS (Chronic Coronary Syndromes) guidelines, and the EAPCI consensus document, they discuss why these conditions remain underdiagnosed—and how structured invasive assessment can make a difference, even in time-constrained clinical environments. This co...
At #EuroPCR2025, Martine Gilard, Antonio Mangieri, and Marco Barbanti share their perspectives on managing coronary artery disease in patients scheduled for TAVI. Is coronary angiography always necessary? When should PCI be performed—before, during, or after the procedure? And how do you decide? Tune in for a practical exchange on strategy, timing, and patient selection! Hosted on Acast. See acast.com/privacy for more information....
Nicola Ryan and Flavio Ribichini discuss the challenges of treating the calcified left main stem. They break down the complexities of this high-risk condition and highlight the role of mechanical circulatory support in everyday practice. They focus on the role of intracoronary imaging as a game-changer and examine the use of one versus two stents, outlining cases where two stents may be necessary. Key takeaways 1. Calcified left main stem disease is complex but can be simplified with the right t...
What does the PREVENT trial tell us about managing vulnerable plaques? Recorded during #europcr 2025, this discussion features Michael Haude and Thomas Cuisset as they review key insights from this major study of over 1,600 patients with physiologically non-significant but vulnerable plaques identified by intracoronary imaging—mainly IVUS. Patients were randomised to receive either optimal medical therapy (OMT) alone or combined with preventive PCI, and followed over several years. While the com...
Stephan Windecker and Flavio Ribichini review the outcomes of the FAITAVI trial, presented during the #europcr 2025 LBT session. As coronary artery disease is the most common cardiac comorbidity in patients undergoing TAVI, the trial set out to evaluate whether physiology-guided decision-making could offer better clarity. When performing diagnostic angiography before TAVI, clinicians often find intermediate coronary lesions that don’t obviously require revascularisation — so what's the right str...
